Evidence map›Paper›PMID 37349951›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2023

Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy.

Björn Peters, Joachim Beige, Justyna Siwy, Michael Rudnicki, Ralph Wendt, Alberto Ortiz, Ana Belen Sanz, Harald Mischak, Heather N Reich, Salmir Nasic and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Björn PetersDepartment of Molecular and Clinical Medicine, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Joachim BeigeKuratorium for Dialysis and Transplantation, Neu Isenburg/Leipzig, Germany.
Justyna SiwyMosaiques diagnostics GmbH, Hannover, Germany.
Michael RudnickiDepartment of Internal Medicine IV - Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
Ralph WendtDivision of Nephrology and KfH Renal Unit, Hospital St Georg, Leipzig, Germany.
Alberto OrtizInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD UAM), Madrid, Spain.ORCID 0000-0002-9805-9523
Ana Belen SanzInstituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD UAM), Madrid, Spain.
Harald MischakMosaiques diagnostics GmbH, Hannover, Germany.
Heather N ReichDepartment of Medicine, University of Toronto and Division of Nephrology, University Health Network, Toronto, Ontario, Canada.
Salmir NasicDepartment of Molecular and Clinical Medicine, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Dana MahmoodDepartment of Public Health and Clinical Medicine, Unit Östersund, Umeå University, Umea, Sweden.
Anders PerssonDepartment of Public Health and Clinical Medicine, Unit Sundsvall, Umeå University, Umea, Sweden.
Anders FernströmDepartment of Nephrology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Maria WeinerDepartment of Nephrology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Bernd StegmayrDepartment of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
PersTIgAN Working Group

Funding

CIHR
6 · The paper itself

Abstract

backgroundImmunoglobulin A nephropathy (IgAN) frequently leads to kidney failure. The urinary proteomics-based classifier IgAN237 may predict disease progression at the time of kidney biopsy. We studied whether IgAN237 also predicts progression later in the course of IgAN.

methodsUrine from patients with biopsy-proven IgAN was analyzed using capillary electrophoresis-mass spectrometry at baseline (IgAN237-1, n = 103) and at follow-up (IgAN237-2, n = 89). Patients were categorized as "non-progressors" (IgAN237 ≤0.38) and "progressors" (IgAN237 >0.38). Estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio slopes were calculated.

resultsMedian age at biopsy was 44 years, interval between biopsy and IgAN237-1 was 65 months and interval between IgAN237-1 and IgAN237-2 was 258 days (interquartile range 71-531). IgAN237-1 and IgAN237-2 values did not differ significantly and were correlated (rho = 0.44, P < .001). Twenty-eight percent and 26% of patients were progressors based on IgAN237-1 and IgAN237-2, respectively. IgAN237 inversely correlated with chronic eGFR slopes (rho = -0.278, P = .02 for score-1; rho = -0.409, P = .002 for score-2) and with ±180 days eGFR slopes (rho = -0.31, P = .009 and rho = -0.439, P = .001, respectively). The ±180 days eGFR slopes were worse for progressors than for non-progressors (median -5.98 versus -1.22 mL/min/1.73 m2 per year for IgAN237-1, P < .001; -3.02 vs 1.08 mL/min/1.73 m2 per year for IgAN237-2, P = .0047). In multiple regression analysis baseline progressor/non-progressor according to IgAN237 was an independent predictor of eGFR180days-slope (P = .001).

conclusionThe urinary IgAN237 classifier represents a risk stratification tool in IgAN also later in the course of the dynamic disease. It may guide patient management in an individualized manner.

Indexed as

Glomerulonephritis, IGAAdultBiomarkersDisease ProgressionGlomerular Filtration RateHumansPrognosisProteomicsBiomarkersbiomarkerCKDglomerulonephritisIgA nephropathyprogressionurine proteomics

Identifiers

PMID37349951
PMCPMC10689155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.